```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable research substance extensively employed in thrombosis investigations. This Fab fragment specifically targets the glycoprotein IIb/IIIa complex on platelets , blocking platelet aggregation . Consequently , it's frequently employed as a technique to examine the pathways underlying thrombosis and to assess the efficacy of anticoagulant therapies. Supply is typically restricted to institutional settings.
```
Abciximab Research: Utilizing The C7E3 Fragment and 143653-53-6 in Scientific Assessments
Ongoing studies into abciximab, a platelet aggregation inhibitor, frequently utilizes the monoclonal antibody C7E3 and the substance identified as 143653-53-6. These tools are crucial for investigating abciximab's mechanism of action, evaluating its efficacy in different patient populations, and elucidating potential indicators of treatment response. Continued investigation leveraging these precise reagents is expected to generate valuable data for improving clinical applications related to cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis read more and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Potential Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 using C7E3
Recent studies demonstrate that Abciximab (identified as 143653-53-6) presents significant investigative potential, particularly when combined with the antibody fragment. Initial findings have that this pairing could enhance patient results in multiple arterial settings. Further examination is directed on understanding the specific mode of interaction between this inhibitor and C7E3, including study of blood clot clumping and vascular preservation.
- Ongoing study efforts aim to optimize administration strategies.
- Laboratory models are being employed to further assess such propositions.
- Human studies are required to thoroughly determine patient benefit.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers requiring this antibody for experimental studies should meticulously assess purity and precise parameters . The compound is typically supplied as a lyophilized powder and detailed analytical information including identity by LC-MS, potency assays, and bacterial endotoxin testing is available. Verify the manufacturer's CoA specifies acceptable ranges for contaminants and meets all quality control criteria .
High-Purity Abciximab Details & Supply
Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its manufacturer. This agent is frequently utilized in cell-based experiments, particularly those involving platelet adhesion and occlusion. Current vendors offer this material in varying amounts , typically ranging from milligram to larger commercial amounts . Kindly recommend reviewing the report of testing to verify purity and suitability for your specific purpose. Moreover, ensure the shelf life date before obtaining to maintain optimal performance .
- Common Purity: >95%
- Keeping Conditions: -20°C or controlled conditions
- Intended Purpose: Platelet Aggregation Blocking Studies